Biosearch Technologies Licenses Access to the New CDC "PDM" H1N1 Signatures

Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has licensed access to the new “pdm” H1N1 signatures from Centers for Disease Control and Prevention (CDC).  The new “pdm” panel is optimized to achieve enhanced sensitivity and specificity for H1N1 specimen.

To read the entire story, read the full press release.